Firm starts phase three of cat allergy trials

Biotech firm Circassia based at the Oxford Science Park, has started phase three trials of cat allergy treatment.

The new study follows encouraging results in previous trials for the ToleroMune vaccine.

Chief executive Steve Harris said: “Tens of millions of people are allergic to cats in the US and Europe, and the disease can have a major effect on patients’ quality of life.”

Related links

click2find

About cookies

We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience. By staying on our website you agree to our use of cookies. Find out more about the cookies we use.

I agree